129 related articles for article (PubMed ID: 21696934)
21. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
Make B; Hanania NA; ZuWallack R; Kalberg C; Emmett A; Brown CP; Knobil K
Clin Ther; 2005 May; 27(5):531-42. PubMed ID: 15978302
[TBL] [Abstract][Full Text] [Related]
22. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
Dalal AA; Candrilli SD; Davis KL
Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
[TBL] [Abstract][Full Text] [Related]
23. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium.
Pepin JL; Cockcroft JR; Midwinter D; Sharma S; Rubin DB; Andreas S
Chest; 2014 Dec; 146(6):1521-1530. PubMed ID: 25058845
[TBL] [Abstract][Full Text] [Related]
24. Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation.
Vanfleteren LE; Spruit MA; Groenen MT; Bruijnzeel PL; Taib Z; Rutten EP; Op 't Roodt J; Akkermans MA; Wouters EF; Franssen FM
Eur Respir J; 2014 May; 43(5):1306-15. PubMed ID: 24311762
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily.
Kerwin EM; Nathan RA; Meltzer EO; Ortega HG; Yancey SW; Schoaf L; Dorinsky PM
Respir Med; 2008 Apr; 102(4):495-504. PubMed ID: 18206361
[TBL] [Abstract][Full Text] [Related]
26. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma.
Weiler JM; Nathan RA; Rupp NT; Kalberg CJ; Emmett A; Dorinsky PM
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):65-72. PubMed ID: 15702819
[TBL] [Abstract][Full Text] [Related]
27. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
Baumgarten C; Geldszus R; Behre U; Peslis N; Trautmann M;
Eur J Med Res; 2002 Jan; 7(1):1-7. PubMed ID: 11827834
[TBL] [Abstract][Full Text] [Related]
28. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
[TBL] [Abstract][Full Text] [Related]
29. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
[TBL] [Abstract][Full Text] [Related]
30. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
[TBL] [Abstract][Full Text] [Related]
31. Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast.
Camargo CA; Boulet LP; Sutherland ER; Busse WW; Yancey SW; Emmett AH; Ortega HG; Ferro TJ
J Asthma; 2010 Feb; 47(1):76-82. PubMed ID: 20100025
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
[TBL] [Abstract][Full Text] [Related]
33. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease.
Ryan S; Doherty LS; Rock C; Nolan GM; McNicholas WT
Respiration; 2010; 79(6):475-81. PubMed ID: 19684384
[TBL] [Abstract][Full Text] [Related]
34. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study.
Ilowite J; Webb R; Friedman B; Kerwin E; Bird SR; Hustad CM; Edelman JM
Ann Allergy Asthma Immunol; 2004 Jun; 92(6):641-8. PubMed ID: 15237766
[TBL] [Abstract][Full Text] [Related]
35. Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate.
Rojas RA; Paluga I; Goldfrad CH; Duggan MT; Barnes N
J Asthma; 2007; 44(6):437-41. PubMed ID: 17654129
[TBL] [Abstract][Full Text] [Related]
36. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
37. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease.
McAllister DA; Maclay JD; Mills NL; Mair G; Miller J; Anderson D; Newby DE; Murchison JT; Macnee W
Am J Respir Crit Care Med; 2007 Dec; 176(12):1208-14. PubMed ID: 17885263
[TBL] [Abstract][Full Text] [Related]
38. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD.
Dalal AA; Shah MB; D'Souza AO; Lunacsek OE; Nagar SP; Crater GD
Respir Res; 2012 May; 13(1):41. PubMed ID: 22651541
[TBL] [Abstract][Full Text] [Related]
39. Aortic Pulse Wave Velocity as a Measure of Cardiovascular Risk in Chronic Obstructive Pulmonary Disease: Two-Year Follow-Up Data from the ARCADE Study.
Gale NS; Albarrati AM; Munnery MM; Mcdonnell BJ; Benson VS; Singer RMT; Cockcroft JR; Shale DJ
Medicina (Kaunas); 2019 Apr; 55(4):. PubMed ID: 30987061
[No Abstract] [Full Text] [Related]
40. Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease.
Koser A; Westerman J; Sharma S; Emmett A; Crater GD
Open Respir Med J; 2010 Oct; 4():86-91. PubMed ID: 21253451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
